Physician profile
Allison M Gaylor
NPI 1114267887
$2,656.72
in general payments reported to CMS, 2019-2025
34 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $713 · 2022: $886 · 2023: $623 · 2024: $309 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.53 |
| Education | $118.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.36 | 2021-2025 | |
| Novo Nordisk INC | $321.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $199.16 | 2021-2025 | Freestyle Libre 2, Assurity, Freestyle Libre 3 |
| Pfizer INC. | $178.76 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.57 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.56 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $85.17 | 2022-2023 | Myrbetriq |
| Lilly USA, LLC | $68.08 | 2021-2023 | Jardiance, Emgality |
| Exact Sciences Corporation | $47.73 | 2023 | Cologuard Collection Kit |
| Almatica Pharma LLC | $46.09 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Impel Pharmaceuticals INC. | $43.89 | 2022-2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $42.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.77 | 2022 | |
| Eisai INC. | $37.83 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $35.66 | 2022-2023 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $34.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.18 | 2022 | |
| Glaxosmithkline, LLC. | $26.94 | 2021 | |
| Merck Sharp & Dohme LLC | $26.47 | 2021-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Arbor Pharmaceuticals, INC. | $25.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.04 | 2023 | |
| Alfasigma USA, INC. | $20.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.28 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.87 | 2023 | Hetlioz |
| Medtronic, INC. | $18.34 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.95 | 2022 | |
| Lundbeck LLC | $16.53 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.02 | 2022 | |
| Amarin Pharma, INC. | $15.46 | 2021 | |
| Lucid Diagnostics INC. | $14.67 | 2023 | |
| Nalu Medical, INC. | $14.61 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.10 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $13.95 | 2023 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $13.85 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Gaylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.